CMN Markets

CMN Markets

The CMN Markets Newsletter will bring you the latest news updates from the stock markets with focus on companies that have clinical-stage programmes involving a gene-editing tool like CRISPR.

CMN Markets April 2022 | CRISPR Stocks and Market...
May. 5, 2022

April was somewhat of a rough month on the stock market, and this impacted biotechnology stocks. On the up side, Verve Therapeutics presented...

CMN Markets March 2022 | CRISPR Stocks and Market...
Apr. 19, 2022

In March, Intellia Therapeutics reported dosing the first patient with its ex vivo candidate NTLA-5001 for acute myeloid leukaemia, and received...

CMN Markets February 2022 | CRISPR Stocks and...
Mar. 3, 2022

Intellia Therapeutics presents new long term-data for in vivo candidate NTLA-2001, and we saw the final outcome of the years-long CRISPR patent...

CMN Markets January 2022 | CRISPR Stocks and...
Feb. 3, 2022

This month, the biotech sector was pressured by macroeconomic trends. The FDA lifts earlier clinical hold on Allogene Therapeutics’ clinical pipeline....

CMN Markets December 2021 | CRISPR Stocks and...
Jan. 6, 2022

Promising updates on clinical and pre-clinical programmes at the American Society of Hematology (ASH) annual meeting. Intellia Therapeutics doses...

CMN Markets November 2021 | CRISPR Stocks and...
Dec. 6, 2021

The biotechnology sector takes a hard hit this month, with heavy declines in stock prices. On a positive note, Verve Therapeutics, Cellectis and...

CMN Markets October 2021 | CRISPR Stocks and...
Nov. 3, 2021

The FDA halts Allogene Therapeutics' AlloCAR trials following chromosomal abnormalities in one patient in ALPHA2 trial. Poseida Therapeutics announces...

CMN Markets September 2021 | CRISPR Stocks and...
Oct. 7, 2021

Editas Medicine presents preliminary data from ongoing Phase 1/2 clinical trial for EDIT-101 in Leber congenital amaurosis 10 (LCA10). Intellia...

close
Search CRISPR Medicine